基于结构-行为-绩效分析范式的药品流通领域供给侧结构性改革策略分析  

Analysis on Supply-side Structural Reform Strategy of Drug Distribution Based on Structure-conduct-performance Analysis Paradigm

作　　者：李璠[1,2] 余伯阳[1] 曹人元[2] 曹亚茹[2] 洪亮[2] 

机构地区：[1]中国药科大学国际医药商学院,南京211198 [2]昆明医科大学药学院暨云南省天然药物药理重点实验室,昆明650500

出　　处：《中国药房》2017年第10期1297-1301,共5页China Pharmacy

基　　金：国家社会科学基金项目(No.14BGL144);云南省天然药物药理重点实验室开放基金(No.2015G001)

摘　　要：目的:为我国药品流通行业开展供给侧结构性改革提供产业组织研究基础和发展建议。方法:运用哈佛学派的结构-行为-绩效(SCP)分析范式对2010年以来我国药品流通行业的市场结构、企业行为、经营绩效进行深入研究。结果:自2010年以来,我国药品流通行业呈规模增速下降、市场集中度降低、行业进入壁垒提高、国有资本主导等态势。尽管企业兼并重组和上市融资规模扩大,管理信息化、第三方物流、"互联网+"和药店联盟等经营模式蓬勃发展,但行业经营绩效差,国有企业整体表现不佳。结论:应针对性地加快推进药品流通行业的供给侧结构性改革,鼓励企业融资兼并,破除地方保护主义,发展合作式第三方医药物流和药店联盟,借力互联网推动行业经营模式的转型升级。OBJECTIVE：To provide basic industrial research and development recommendations for the supply-side structural reform in drug distribution in China. METHODS：Structure-conduct-performance（SCP）analysis paradigm from Harvard was used for in-depth study of market structure,business conduct and business performance in China since 2010. RESULTS：Since 2010,drug distribution industry in China had shown the scale of decline in the growth rate,low market concentration,increased barriers to entry,the leading of state-owned capital,etc. Though corporate mergers and acquisitions and public financing expanded the scale,management information,third-party logistics,＂Internet＋＂and pharmacy alliance business model flourished,the industry operating performance was poor,state-owned enterprises showed poor performance. CONCLUSIONS：The transformation and upgrading of the industry business model should be promoted by targetedly accelerating the supply-side structural reforms in the drug distribution industry,encouraging corporate finance mergers,breaking local protectionism,developing cooperative pharmacies and pharmaceutical third-party logistics alliances and leveraging the Internet.

关 键 词：结构-行为-绩效分析 药品流通 供给侧改革 产业结构升级 

分 类 号：R979.5[医药卫生—药品]